GlassScriptPhysician profile
Irina Godes
NPI 1003896366
$698.54
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.17 · 2021: $11.98 · 2022: $46.24 · 2023: $302 · 2024: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $588.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $112.80 | 2024 | Dupixent |
| Glaxosmithkline, LLC. | $87.74 | 2019-2024 | Arexvy, Shingrix, Bexsero |
| Cranial Technologies, INC | $69.08 | 2019-2024 | Doc Band |
| Novo Nordisk INC | $66.20 | 2023-2024 | Wegovy, Saxenda |
| Sanofi Pasteur INC. | $64.39 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $63.29 | 2022-2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $42.80 | 2024 | Gardasil 9, Vaxelis, Gardasil |
| Hologic Sales and Service, LLC | $31.74 | 2023 | Aptima, Thinprep 2000 Processor |
| Shield Therapeutics INC | $28.32 | 2023 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $23.03 | 2023 | |
| Genzyme Corporation | $22.90 | 2023 | |
| Dexcom, INC. | $20.08 | 2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $20.02 | 2024 | |
| Phadia US INC. | $16.90 | 2024 | Immunocap |
| Scilex Pharmaceuticals INC. | $15.58 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $13.67 | 2024 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irina Godes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.